What are they? Lipid nanoparticles (LNPs) are a crucial component in the delivery of RNA drugs, including mRNA-based therapeutics and small interfering RNA (siRNA) molecules. LNPs are utilized to protect and transport these fragile RNA molecules through the cell membrane to their target cells, ensuring efficient delivery and therapeutic effects.
mRNA Delivery by Viral Vectors
What is it? mRNA delivery by viral vectors is a promising approach in the field of gene therapy and vaccine development. Viral vectors are modified viruses that can be used to deliver genetic material, such as mRNA, into target cells. This technology has gained significant attention, especially in mRNA-based COVID-19 vaccine development, which has demonstrated …
Oligonucleotide Therapeutics: Drug-Drug Interactions (DDI)
What is it? It is unavoidable for patients to have no other substances in their body when being administered a treatment. Whether it is a daily vitamin, over the counter drug, prescribed medication or even the food patients eat daily, it is important to understand if and how administered drugs interact with these substances. Drug-drug …
Oligonucleotide Anti-Drug Antibodies (ADAs)
What is it? An anti-drug antibody, ADA, is an antibody that binds to the therapeutic drug. They are formed as an immune response when a drug is administered to a patient’s body. The problem that arises with ADAs is that they also have the potential to be immunogenic themselves. Once the ADAs are formed, they …
Understanding Therapeutic Oligonucleotides ADME
Therapeutic oligonucleotides are important for altering targeted RNA pathways through a variety of mechanisms, making them a versatile tool in drug development. Understanding their ADME properties is a critical step in drug development because it will make us aware of the potential side effects certain oligo treatments may have. This allows us to create methods …
